Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells

Safaei, Mohsen; Khosravian, Pegah; Sheykhshabani, Sedighe Kazemi; Mardani, Gashtasb; Elahian, Fatemeh; Mirzaei, Seyed Abbas

doi:10.1016/j.taap.2022.115989

Cited by 14 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, several promising nano-delivery systems have been developed for systemic administration and improved tumor-targeted delivery while minimizing side effects. For instance, Safaei et al [ 40 ] developed a transmembrane peptide (TAT)-conjugated liposomal nanocarrier for the delivery of trastuzumab and siRNA targeting breast cancer resistance protein (BCRP) to overcome multidrug resistance in breast cancer. Similarly, Saraswat and colleagues developed an oral lipid nanoparticle-based delivery system encapsulating ARV-825 and vemurafenib (VEM) for the treatment of BRAFi-resistant melanoma [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer

Wu,

Zhang,

Zhao

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Cisplatin (DDP) resistance, often leading to first-line chemotherapy failure in non-small cell lung cancer (NSCLC), poses a significant challenge. MiR-219a-5p has been reported to enhance the sensitivity of human NSCLC to DDP. However, free miR-219a-5p is prone to degradation by nucleases in the bloodstream, rendering it unstable. In light of this, our study developed an efficient nanodrug delivery system that achieved targeted delivery of DDP and miR-219a-5p by modifying liposomes with folate (FA). Based on the results of material characterization, we successfully constructed a well-dispersed and uniformly sized (approximately 135.8 nm) Lipo@DDP@miR-219a-5p@FA nanodrug. Agarose gel electrophoresis experiments demonstrated that Lipo@DDP@miR-219a-5p@FA exhibited good stability in serum, effectively protecting miR-219a-5p from degradation. Immunofluorescence and flow cytometry experiments revealed that, due to FA modification, Lipo@DDP@miR-219a-5p@FA could specifically bind to FA receptors on the surface of tumor cells (A549), thus enhancing drug internalization efficiency. Safety evaluations conducted in vitro demonstrated that Lipo@DDP@miR-219a-5p@FA exhibited no significant toxicity to non-cancer cells (BEAS-2B) and displayed excellent blood compatibility. Cellular functional experiments, apoptosis assays, and western blot demonstrated that Lipo@DDP@miR-219a-5p@FA effectively reversed DDP resistance in A549 cells, inhibited cell proliferation and migration, and further promoted apoptosis. In summary, the Lipo@DDP@miR-219a-5p@FA nanodrug, through specific targeting of cancer cells and reducing their resistance to DDP, significantly enhanced the anti-NSCLC effects of DDP in vitro, providing a promising therapeutic option for the clinical treatment of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer

Wu,

Zhang,

Zhao

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

show abstract

“…Strategies such as the development of chemotherapy agents, finding new drug carriers and combination treatments have been suggested to overcome these barriers (Kokubo et al, 2021; Qing et al, 2019; Safaei et al, 2022). Identification of natural compounds that could be used as anticancer drugs has significantly reduced the mortality rate of cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Paynantheine more effectively reverses multidrug resistance in malignant EPG85.257RDB and MCF7MX cells than morphine and speciociliatine

Abdali,

Nadipour Borujeni,

Hosseini

et al. 2024

Cell Biology International

Self Cite

View full text Add to dashboard Cite

The possible interactions of morphine, paynantheine and speciociliatine alkaloids with ATP‐binding cassette (ABC) transporters was investigated. The compounds were docked against ABCG2 and ABCB1 to predict the binding mode of alkaloids in active binding sites. The cytotoxicity of morphine, paynantheine and speciociliatine for EPG85.257RDB and MCF7MX cells was determined and ABCB1 and ABCG2 gene and protein expression were determined. The binding score of paynantheine to ABCB1 was higher in the docking studies. Paynantheine and speciociliatine had similar binding scores to ABCB1, but higher binding scores to ABCG2 than did morphine. Paynantheine and speciociliatine were more effective against MCF7MX and EPG85.257RDB cells and showed greater cyctotoxicity in the MTT assay. The effect of morphine and paynantheine on the ABCB1 gene and protein expression suggests these compounds can reduce resistance in cancer patients, but that speciociliatine may not be a suitable candidate because of its increased ABCB1 expression while speciociliatine decreased the expression of ABCG2 in MCF7MX cells. This indicates that speciociliatine is a better candidate for reducing drug resistance in this cell line. Structural modification, drug‐metabolizing enzymes and differences in the binding sites could cause functional differences between these compounds.

show abstract

“…Liposomes, lipid bilayer vesicles, have gained popularity as drug/gene delivery systems due to their efficiency, biocompatibility, non-immunogenicity, increased solubility of agents, and capacity to encapsulate a wide variety of drugs. [5] Liposomes are carriers with a cellular-membrane-like lipid bilayer surrounding an aqueous phase and represent fair features for ophthalmic drug delivery. [6] Liposome-containing formulations allow us to control the transportation of medicines into particular organs during the optimized time, leading to improved safety and efficacy of treatment.…”

Section: Introductionmentioning

confidence: 99%

“…The liposomal delivery system (LDS) effectively transfers active agents into compartmentalized structures, including living cells. Liposomes, lipid bilayer vesicles, have gained popularity as drug/gene delivery systems due to their efficiency, biocompatibility, non‐immunogenicity, increased solubility of agents, and capacity to encapsulate a wide variety of drugs [5] . Liposomes are carriers with a cellular‐membrane‐like lipid bilayer surrounding an aqueous phase and represent fair features for ophthalmic drug delivery [6] .…”

Section: Introductionmentioning

confidence: 99%

Development of a Liposomal Gel for Prolonged Ophthalmic Soluble Drug Delivery

et al. 2023

View full text Add to dashboard Cite

Liposome, as a drug delivery vehicle, entraps drugs, releases them sustainably, and modifies release patterns. This entrapment has diminished exposure of the drug to the eye medium, which could minimize adverse effects. In this investigation, 18 formulations in 3 key categories (liposome, gel and lipogel) of cromolyn sodium (CS) were prepared and evaluated as a water‐soluble drug. Then, liposome formulations (L1‐L6) were developed using the thin‐film hydration method. The macroscopic and microscopic assessments comprised drug entrapment efficiency, release rate, release mechanism, liposome stability, and vesicle size were evaluated to evaluate liposomes and lipogel. The results revealed that applying cholesterol in formulations ranging from 33 % to 44 % w/w increased the liposome drug entrapment efficiency, stability, and release time. The optimum phosphatidylcholine (PC) ratio to cholesterol in the L4 formulation was 2 : 1, which prolonged drug release time by up to 5 hours. The carbomer® 934 containing lipogel (0.5 % w/v) showed the longest release time (9 hours) with a zero‐order release. CS release from HPMC (2 % w/v) lipogel was assumed to follow first‐order release kinetics. The prolongation of drug release time in a carboxymethylcellulose lipogels was shorter than carbomer® 934 (5 hours). Finally, a sustained release formulation of CS liposome was produced; it was developed as lipogels to enhance its release duration; finally, release kinetic were modified.

show abstract

Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells

Cited by 14 publications

References 36 publications

Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer

Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer

Paynantheine more effectively reverses multidrug resistance in malignant EPG85.257RDB and MCF7MX cells than morphine and speciociliatine

Development of a Liposomal Gel for Prolonged Ophthalmic Soluble Drug Delivery

Contact Info

Product

Resources

About